- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.09. | SIRNAOMICS-B (02257): SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| 05.09. | SIRNAOMICS-B (02257): INTERIM REPORT 2025 | 2 | HKEx | ||
| 01.09. | SIRNAOMICS-B (02257): RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR, APPOINTMENT OF NON-EXECUTIVE DIRECTOR, INDEPENDENT NON-EXECUTIVE DIRECTOR, CHANGE ... | - | HKEx | ||
| 01.09. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 28.08. | SIRNAOMICS-B (02257): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
| SIRNAOMICS Aktie jetzt für 0€ handeln | |||||
| 18.08. | SIRNAOMICS-B (02257): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| 22.07. | SIRNAOMICS-B (02257): RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| 03.07. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 03.07. | SIRNAOMICS-B (02257): APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 20.06. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 20.06. | SIRNAOMICS-B (02257): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2025 | - | HKEx | ||
| 05.06. | SIRNAOMICS-B (02257): TERMS OF REFERENCE FOR NOMINATION COMMITTEE UNDER THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): PROXY FORM | 1 | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): ANNUAL REPORT 2024 | - | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 | - | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND BUY BACK SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED RE-APPOINTMENT ... | - | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 23.04. | SIRNAOMICS-B (02257): CESSATION OF HONORARY SCIENTIFIC ADVISOR | - | HKEx | ||
| 27.03. | SIRNAOMICS-B (02257): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
| 04.10.24 | XFRA V5Z: WIEDERAUFNAHME/RESUMPTION | 316 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
| APOGEE THERAPEUTICS | 36,860 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| IMMUNOVANT | 15,530 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCELLX | 75,20 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 36,210 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| BEAM THERAPEUTICS | 21,280 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 16,930 | 0,00 % | Arcutis bei H.C. Wainwright: Strategisches Wachstum und Pipeline-Entwicklung | ||
| AVIDITY BIOSCIENCES | 40,190 | 0,00 % | Avidity Biosciences schließt Kapitalerhöhung über 690 Millionen US-Dollar ab | ||
| CG ONCOLOGY | 34,600 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
| RAPPORT THERAPEUTICS | 24,730 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | ||
| TOURMALINE BIO | 47,650 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 6,930 | 0,00 % | Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa | DJ Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa
Von Adriano Marchese
DOW JONES--Novartis hat eine potenziell milliardenschwere Entwicklungspartnerschaft mit dem US-Biotechunternehmen... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,850 | 0,00 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,065 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,410 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report |
Das Unternehmen SIRNAOMICS LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,840 Euro und damit -8,91 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIRNAOMICS LTD finden Sie auf Wallstreet Online.